Secukinumab for Psoriatic Arthritis

Patients with moderate-to-severe psoriasis seem to have a greater risk for developing psoriatic arthritis. Therefore, it is not surprising that new agents for either psoriasis or psoriatic arthritis are tested for both conditions. In this industry-funded, phase III study, investigators randomized 397 adults with active psoriatic arthritis to receive placebo or a human anti-interleukin-17A monoclonal antibody (secukinumab) subcutaneously in doses of 300 mg, 150 mg, and 75 mg weekly for 4 weeks then …